15 min ago
ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2014 Financial Results
ImmunoGen, Inc . , a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate technology, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, April 25, 2014, to discuss ImmunoGen's financial results for the three-month period ended March 31, 2014.
Trending on the Topix Network
4 hrs ago
Press release distribution, EDGAR filing, XBRL, regulatory filings
Peluso, 42, is Chief Executive Officer of Gil... )--The GEO Group, Inc. will release its first quarter 2014 financial results on Tuesday, April 29, 2014 before the market opens.
Wed Apr 16, 2014
Wednesday Sector Leaders: Biotechnology, Rubber & Plastics
In trading on Wednesday, biotechnology shares were relative leaders, up on the day by about 2%.
Wednesday's ETF Movers: FBT, GDX
In trading on Wednesday, the First Trust NYSE Arca Biotechnology Index Fund ETF is outperforming other ETFs, up about 2.6% on the day.
Immunogen Rating Reiterated by Canaccord Genuity
's stock had its "buy" rating reaffirmed by investment analysts at Canaccord Genuity in a note issued to investors on Wednesday, American Banking and Market News reports.
Thu Apr 10, 2014
Pre-Market Scans on Top Gainers -- Research on Athlon Energy,...
The session saw a positive impact from Information Technology, Health Care and Materials sectors along with a drag from Utilities and Telecommunication Services sectors.
Stocks to Watch Thursday: VIVUS, Inc., Zillow Inc, and ImmunoGen, Inc.
Interestingly, short-term call open interest has almost doubled since March 24, while put open interest climbed less than 1%.
Tue Apr 08, 2014
ImmunoGen, Inc. Announces First Clinical Findings with Refined Dosing Strategy for IMGN853
The data were presented at the American Association for Cancer Research Annual Meeting in San Diego, CA.
Mon Apr 07, 2014
Immunogen Rating Increased to Outperform at Zacks
The firm currently has a $15.90 target price on the stock. Zacks 's price objective suggests a potential upside of 19.64% from the company's previous close.
Tue Apr 01, 2014
SAGE Therapeutics Appoints Howard H. Pien to the Companya s Board of Directors
"Howard is a seasoned industry leader with deep biopharmaceutical expertise, especially in guiding companies as they expand and evolve from research and development to clinical stage," said Jeff Jonas, M.D., chief executive officer of SAGE Therapeutics.
Fri Mar 28, 2014
Friday's ETF Movers: GXC, FBT
Components of that ETF showing particular strength include shares of , up about 7.8% on the day.
Thu Mar 20, 2014
ImmunoGen Schedules Presentations by Company Scientists at Upcoming AACR Annual Meeting
"They also include highly encouraging preclinical findings with both our IMGN289 and IMGN853 compounds, as well as data on some of the more recent additions to our ADC technology portfolio."